PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics

Ovarian cancer is the most lethal gynecologic malignancy in the United States, with an estimated 22,530 new cases and 13,980 deaths in 2019. Recent studies have indicated that the phosphoinositol 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), as well as the nuclear fact...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2019-07, Vol.11 (7), p.949
Main Authors: Ghoneum, Alia, Said, Neveen
Format: Article
Language:English
Subjects:
1-Phosphatidylinositol 3-kinase
AKT protein
Angiogenesis
Cancer therapies
Cell cycle
Cell growth
Chromosomes
Enzymes
Growth factors
Kinases
Lymphocytes B
Malignancy
Medical prognosis
Metabolism
Metastasis
Mutation
NF-κB protein
Ovarian cancer
Protein expression
Proteins
Rapamycin
Review
Survival analysis
TOR protein
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c351t-4797c280ff0f5620366bb28eb0d57af280c073fba55afed578dbe31493ada6d23
cites cdi_FETCH-LOGICAL-c351t-4797c280ff0f5620366bb28eb0d57af280c073fba55afed578dbe31493ada6d23
container_end_page
container_issue 7
container_start_page 949
container_title Cancers
container_volume 11
creator Ghoneum, Alia
Said, Neveen
description Ovarian cancer is the most lethal gynecologic malignancy in the United States, with an estimated 22,530 new cases and 13,980 deaths in 2019. Recent studies have indicated that the phosphoinositol 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), as well as the nuclear factor-κ light chain enhancer of activated B cells (NFκB) pathways are highly mutated and/or hyper-activated in a majority of ovarian cancer patients, and are associated with advanced grade and stage disease and poor prognosis. In this review, we will investigate PI3K/AKT/mTOR and their interconnection with NFκB pathway in ovarian cancer cells.
doi_str_mv 10.3390/cancers11070949
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6679095</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2254509242</sourcerecordid><originalsourceid>FETCH-LOGICAL-c351t-4797c280ff0f5620366bb28eb0d57af280c073fba55afed578dbe31493ada6d23</originalsourceid><addsrcrecordid>eNpdkc9O3DAQxq2qqKCFc2-VpV56CevYsb3uoRKsoF2BWFSll16siWOzRomz2MkiXo2H6DM1yz8Bvtia-c03nvkQ-pyTQ8YUmRoIxsaU50QSVagPaI8SSTMhVPHx1XsXHaR0TcbDWC6F_IR2WU5nRSHkHvp7uWBn2dFZmbXl8jeGUOOL03_3x_gS-tUt3CXsA15uIHoIeP7Q8DtetOvGG-h9FxJ2XcQlxCvb2xqXKxthbYfem7SPdhw0yR483RP05_SknP_Kzpc_F_Oj88wwnvdZIZU0dEacI44LSpgQVUVntiI1l-DGjCGSuQo4B2fH2KyuLMsLxaAGUVM2QT8edddD1dra2NBHaPQ6-hbine7A67eZ4Ff6qttoIaQiio8C354EYncz2NTr1idjmwaC7YakKeUFJ4oW215f36HX3RDDOJ4eIcnHvfItNX2kTOxSita9fCYnemudfmfdWPHl9Qwv_LNR7D-ZZJXf</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2547512852</pqid></control><display><type>article</type><title>PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics</title><source>Publicly Available Content (ProQuest)</source><source>PubMed</source><creator>Ghoneum, Alia ; Said, Neveen</creator><creatorcontrib>Ghoneum, Alia ; Said, Neveen</creatorcontrib><description>Ovarian cancer is the most lethal gynecologic malignancy in the United States, with an estimated 22,530 new cases and 13,980 deaths in 2019. Recent studies have indicated that the phosphoinositol 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), as well as the nuclear factor-κ light chain enhancer of activated B cells (NFκB) pathways are highly mutated and/or hyper-activated in a majority of ovarian cancer patients, and are associated with advanced grade and stage disease and poor prognosis. In this review, we will investigate PI3K/AKT/mTOR and their interconnection with NFκB pathway in ovarian cancer cells.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers11070949</identifier><identifier>PMID: 31284467</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>1-Phosphatidylinositol 3-kinase ; AKT protein ; Angiogenesis ; Cancer therapies ; Cell cycle ; Cell growth ; Chromosomes ; Enzymes ; Growth factors ; Kinases ; Lymphocytes B ; Malignancy ; Medical prognosis ; Metabolism ; Metastasis ; Mutation ; NF-κB protein ; Ovarian cancer ; Protein expression ; Proteins ; Rapamycin ; Review ; Survival analysis ; TOR protein ; Tumors</subject><ispartof>Cancers, 2019-07, Vol.11 (7), p.949</ispartof><rights>2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 by the authors. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c351t-4797c280ff0f5620366bb28eb0d57af280c073fba55afed578dbe31493ada6d23</citedby><cites>FETCH-LOGICAL-c351t-4797c280ff0f5620366bb28eb0d57af280c073fba55afed578dbe31493ada6d23</cites><orcidid>0000-0002-7904-2558</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2547512852/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2547512852?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31284467$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ghoneum, Alia</creatorcontrib><creatorcontrib>Said, Neveen</creatorcontrib><title>PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Ovarian cancer is the most lethal gynecologic malignancy in the United States, with an estimated 22,530 new cases and 13,980 deaths in 2019. Recent studies have indicated that the phosphoinositol 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), as well as the nuclear factor-κ light chain enhancer of activated B cells (NFκB) pathways are highly mutated and/or hyper-activated in a majority of ovarian cancer patients, and are associated with advanced grade and stage disease and poor prognosis. In this review, we will investigate PI3K/AKT/mTOR and their interconnection with NFκB pathway in ovarian cancer cells.</description><subject>1-Phosphatidylinositol 3-kinase</subject><subject>AKT protein</subject><subject>Angiogenesis</subject><subject>Cancer therapies</subject><subject>Cell cycle</subject><subject>Cell growth</subject><subject>Chromosomes</subject><subject>Enzymes</subject><subject>Growth factors</subject><subject>Kinases</subject><subject>Lymphocytes B</subject><subject>Malignancy</subject><subject>Medical prognosis</subject><subject>Metabolism</subject><subject>Metastasis</subject><subject>Mutation</subject><subject>NF-κB protein</subject><subject>Ovarian cancer</subject><subject>Protein expression</subject><subject>Proteins</subject><subject>Rapamycin</subject><subject>Review</subject><subject>Survival analysis</subject><subject>TOR protein</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdkc9O3DAQxq2qqKCFc2-VpV56CevYsb3uoRKsoF2BWFSll16siWOzRomz2MkiXo2H6DM1yz8Bvtia-c03nvkQ-pyTQ8YUmRoIxsaU50QSVagPaI8SSTMhVPHx1XsXHaR0TcbDWC6F_IR2WU5nRSHkHvp7uWBn2dFZmbXl8jeGUOOL03_3x_gS-tUt3CXsA15uIHoIeP7Q8DtetOvGG-h9FxJ2XcQlxCvb2xqXKxthbYfem7SPdhw0yR483RP05_SknP_Kzpc_F_Oj88wwnvdZIZU0dEacI44LSpgQVUVntiI1l-DGjCGSuQo4B2fH2KyuLMsLxaAGUVM2QT8edddD1dra2NBHaPQ6-hbine7A67eZ4Ff6qttoIaQiio8C354EYncz2NTr1idjmwaC7YakKeUFJ4oW215f36HX3RDDOJ4eIcnHvfItNX2kTOxSita9fCYnemudfmfdWPHl9Qwv_LNR7D-ZZJXf</recordid><startdate>20190705</startdate><enddate>20190705</enddate><creator>Ghoneum, Alia</creator><creator>Said, Neveen</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7904-2558</orcidid></search><sort><creationdate>20190705</creationdate><title>PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics</title><author>Ghoneum, Alia ; Said, Neveen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c351t-4797c280ff0f5620366bb28eb0d57af280c073fba55afed578dbe31493ada6d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>1-Phosphatidylinositol 3-kinase</topic><topic>AKT protein</topic><topic>Angiogenesis</topic><topic>Cancer therapies</topic><topic>Cell cycle</topic><topic>Cell growth</topic><topic>Chromosomes</topic><topic>Enzymes</topic><topic>Growth factors</topic><topic>Kinases</topic><topic>Lymphocytes B</topic><topic>Malignancy</topic><topic>Medical prognosis</topic><topic>Metabolism</topic><topic>Metastasis</topic><topic>Mutation</topic><topic>NF-κB protein</topic><topic>Ovarian cancer</topic><topic>Protein expression</topic><topic>Proteins</topic><topic>Rapamycin</topic><topic>Review</topic><topic>Survival analysis</topic><topic>TOR protein</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ghoneum, Alia</creatorcontrib><creatorcontrib>Said, Neveen</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Biological Sciences</collection><collection>ProQuest research library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ghoneum, Alia</au><au>Said, Neveen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2019-07-05</date><risdate>2019</risdate><volume>11</volume><issue>7</issue><spage>949</spage><pages>949-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Ovarian cancer is the most lethal gynecologic malignancy in the United States, with an estimated 22,530 new cases and 13,980 deaths in 2019. Recent studies have indicated that the phosphoinositol 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), as well as the nuclear factor-κ light chain enhancer of activated B cells (NFκB) pathways are highly mutated and/or hyper-activated in a majority of ovarian cancer patients, and are associated with advanced grade and stage disease and poor prognosis. In this review, we will investigate PI3K/AKT/mTOR and their interconnection with NFκB pathway in ovarian cancer cells.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>31284467</pmid><doi>10.3390/cancers11070949</doi><orcidid>https://orcid.org/0000-0002-7904-2558</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2072-6694
ispartof Cancers, 2019-07, Vol.11 (7), p.949
issn 2072-6694
2072-6694
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6679095
source Publicly Available Content (ProQuest); PubMed
subjects 1-Phosphatidylinositol 3-kinase
AKT protein
Angiogenesis
Cancer therapies
Cell cycle
Cell growth
Chromosomes
Enzymes
Growth factors
Kinases
Lymphocytes B
Malignancy
Medical prognosis
Metabolism
Metastasis
Mutation
NF-κB protein
Ovarian cancer
Protein expression
Proteins
Rapamycin
Review
Survival analysis
TOR protein
Tumors
title PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T17%3A43%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PI3K-AKT-mTOR%20and%20NF%CE%BAB%20Pathways%20in%20Ovarian%20Cancer:%20Implications%20for%20Targeted%20Therapeutics&rft.jtitle=Cancers&rft.au=Ghoneum,%20Alia&rft.date=2019-07-05&rft.volume=11&rft.issue=7&rft.spage=949&rft.pages=949-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers11070949&rft_dat=%3Cproquest_pubme%3E2254509242%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c351t-4797c280ff0f5620366bb28eb0d57af280c073fba55afed578dbe31493ada6d23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2547512852&rft_id=info:pmid/31284467&rfr_iscdi=true